Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Q2 2023 Earnings Presentation
11 slides from Sanara Medtech's earnings presentation, 2023
Slide 1: Q2 2023 Earnings and Business Update Call
Q2 2023 Earnings and Business Update Call
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All statements othe
Slide 3: Overview: Commentary on Q2 2023
Overview Commentary on Q2 2023 • Financial Update • Highest net revenue quarter in the Company’s history ($15.8 million). • Loss before income taxes narrowed from $3.4 million to $1.9 million in Q2 YOY. • Net loss of $1.9 million in Q2 2023 compared to $0.8 million of net income in Q2 2022. The high
Slide 4: Surgical Sales
Surgical Sales Sales Overview • Our products were sold in over 950 hospitals/ASCs across 33 states(1) in the TTM • Our products were contracted or approved to be sold in more than 3,000 hospitals/ASCs as of June 30, 2023 ─ Q2 increase over Q1 was due to an agreement signed with a major group purchas
Slide 5: Surgical Sales (continued)
Surgical Sales (continued) Sales Overview • Actions taken and future plans to address the slow down in revenue growth include: - Hiring increased in Q1 and is expected to continue through the end of the year in accordance with our plan - Vetting and training of new hires has improved and will contin
Slide 6: Value-Based Post Acute Wound Care Strategy
Value-Based Post Acute Wound Care Strategy Overview • Sam Muppalla, an experienced wound care executive in the post acute market, hired to lead this initiative. • We have developed a detailed value-based strategy and received initial validation from the market. ─ This strategy will include our exist
Slide 7: BIASURGE – Product Launch
BIASURGE – Product Launch Launch Details • Product is 510(k) cleared and product launch is estimated to occur in mid- Q4 2023. • Manufacturing runs have been scheduled • Currently being tested by clinical partners to ensure a smooth launch and adoption within key facilities 7
Slide 8: Collagen Products Asset Acquisition
Collagen Products Asset Acquisition Overview Strategic Rationale Consideration • Assets acquired from the sellers include: • Gives Sanara control of the • Total initial consideration of $15.25 manufacturing process for CellerateRX million consisting of $9.75 million in cash • Four 510(k) cleared col
Slide 9: Q2 2023 Financial Highlights
Q2 2023 Financial Highlights Overview • Revenue • For the three months ended June 30, 2023, we generated net revenues of $15.8 million compared to net revenues of $9.7 million for the three months ended June 30, 2022, a 63% increase from the prior year period. • For the six months ended June 30, 202
Slide 10: 2023 Financial Highlights (Continued)
2023 Financial Highlights (Continued) Overview (Continued) • R&D Expenses • R&D expenses for the three months ended June 30, 2023, were $1.2 million compared to $1.1 million for the three months ended June 30, 2022. • R&D expenses for the six months ended June 30, 2023, were $2.5 million compared to
Slide 11: Questions
u Questions Evidence Based Healing